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Background: Exercise is beneficial for breast cancer patients during chemotherapy but adherence to different types
and doses of exercise is a challenge. The purpose of this study was to examine predictors of adherence to different
types and doses of exercise during breast cancer chemotherapy in a multicenter randomized controlled trial.
Methods: Breast cancer patients in Edmonton, Vancouver, and Ottawa, Canada receiving chemotherapy (N = 301)
were randomized to a standard dose of 25–30 minutes of aerobic exercise (STAN), a higher dose of 50–60 minutes
of aerobic exercise (HIGH), or a higher dose of 50–60 minutes of combined aerobic and resistance exercise (COMB).
Predictors included demographic, medical, fitness, and quality of life variables. Exercise adherence was measured as
the percentage of supervised exercise sessions completed.
Results: Overall adherence to the supervised exercise sessions was 73% (SD = 24%). In a multivariate regression
model, six independent predictors explained 26.4% (p < 0.001) of the variance in exercise adherence. Higher
exercise adherence was achieved by breast cancer patients in Vancouver (p < 0.001), with fewer endocrine
symptoms (p = 0.009), randomized to STAN (p = 0.009), with fewer exercise limitations (p = 0.009), receiving shorter
chemotherapy protocols (p = 0.015), and with higher VO2peak (p = 0.017). Disease stage (p for interaction = 0.015)
and body mass index (p for interaction = 0.030) interacted with group assignment to predict adherence. For disease
stage, patients with stage I/IIa disease adhered equally well to all three exercise interventions whereas patients with
stage IIb/III disease adhered better to the STAN intervention than the two higher dose exercise interventions. For
body mass index, healthy weight patients adhered equally well to all three exercise interventions whereas
overweight patients adhered best to STAN and worst to COMB; and obese patients adhered best to STAN and
worst to HIGH.
Conclusions: Determinants of exercise adherence in breast cancer patients receiving chemotherapy are
multidisciplinary and may vary by the exercise prescription.
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Exercise during breast cancer chemotherapy improves
physical functioning, fatigue, quality of life, and other
symptoms [1]; and may even improve chemotherapy
completion rate [2] and disease-free survival [3]. More-
over, higher doses of aerobic or combined exercise may
provide additional benefits beyond a standard dose of aer-
obic exercise. In the Combined Aerobic and Resistance
Exercise (CARE) Trial, we compared a thrice weekly
standard dose of 25–30 minutes of moderate-to-vigorous
intensity aerobic exercise (STAN) to a higher dose of 50–
60 minutes of aerobic exercise (HIGH) and a higher dose
of 50–60 minutes of combined aerobic and resistance ex-
ercise (COMB) in 301 breast cancer patients receiving
chemotherapy. In the primary paper [4], we found several
positive effects of the higher dose interventions compared
to STAN for physical functioning, endocrine symptoms
(e.g., hot flashes, night sweats), pain, and health-related
fitness. In secondary papers, we also found that the higher
dose interventions were more effective than STAN for
managing sleep quality [5] and depressive symptoms in
patients with clinical levels of depressive symptoms at
baseline [6].
Unfortunately, adherence to exercise during breast can-
cer chemotherapy is challenging for any exercise interven-
tion—let alone for higher dose interventions—due to
the many side effects of treatments [7,8]. In the present
study, we examined the predictors of exercise adherence
in the CARE Trial. It is possible that breast cancer and/or
chemotherapy-related variables may be unique determi-
nants of exercise and/or they may amplify or nullify the
predictive utility of other previously established determi-
nants [9]. It is also possible that the determinants of
higher dose exercise, or combined exercise, may be differ-
ent than for standard dose exercise during breast cancer
chemotherapy. Such data may be useful in developing tar-
geted behavioral interventions to achieve better adherence
to higher dose exercise interventions, thereby improving
outcomes. To our knowledge, the CARE Trial is only the
second trial to examine the determinants of exercise ad-
herence during breast cancer chemotherapy, and the first
to examine if the determinants of exercise adherence may
vary based on the dose and type of exercise intervention.
Our hypotheses were based on the Supervised Trial of
Aerobic versus Resistance Training (START) that com-
pared aerobic exercise and resistance exercise to usual
care in 242 breast cancer patients receiving chemotherapy
[2]. In that trial, we found that higher cardiovascular fit-
ness, lower body fat, more advanced disease stage, higher
education, less depression, and being a non-smoker
predicted better exercise adherence. Moreover, given the
large sample size in the CARE Trial (N = 301), we were
able to explore potential interactions between these pre-
dictors and group assignment to directly test whetherthe predictors of exercise adherence during breast cancer
chemotherapy differed by exercise type or dose.
Methods
Setting and participants
The main CARE Trial methods have been reported [4].
Briefly, the CARE Trial was a multicenter Canadian trial
with sites in Edmonton, Ottawa, and Vancouver. Ethics
approval was received from the Alberta Cancer Research
Ethics Board and informed consent was obtained from
all participants. Eligibility criteria included English or French
speaking non-pregnant women ≥ 18 years old with stage I –
IIIc breast cancer initiating adjuvant chemotherapy. Women
were excluded if they had incomplete axillary surgery,
transabdominal rectus abdominus muscle reconstructive
surgery, significant health problems, or were not approved
by their oncologist. Eligible participants were identified by
their treating oncologist prior to chemotherapy.
Randomization
After all baseline assessments, participants were strati-
fied by center and chemotherapy regimen (any Herceptin
versus no Herceptin/any taxane versus no Herceptin/no
taxane) and randomly assigned in a 1:1:1 ratio to STAN,
COMB, or HIGH using a computer-generated program.
The allocation sequence was generated in Edmonton and
concealed from the project directors who assigned partici-
pants to groups.
Exercise training interventions
The exercise training interventions have been previously
described [4]. Briefly, participants exercised for the dur-
ation of their chemotherapy beginning within 1–2 weeks
of starting chemotherapy and ending 3–4 weeks after
chemotherapy. The STAN group were asked to follow the
Physical Activity Guidelines for Americans [10] which
have been endorsed for cancer survivors [11,12]. These
guidelines recommend the equivalent of a minimum of
75 minutes/week of vigorous aerobic exercise spread over
3 days/week (i.e., 25–30 minutes/session). The HIGH
group were asked to follow double the minimum guide-
lines of 150 minutes/week of vigorous aerobic exercise per
week (i.e., 50–60 minutes/session). The COMB group
were asked to complete the same aerobic exercise guide-
line as STAN plus a standard strength training program
for 3 days/week consisting of two sets of 10–12 repetitions
of 9 different strength exercises at 60-75% of their esti-
mated 1 repetition maximum (i.e., about 50–60 minutes
of combined exercise). The strength exercises were leg
extension, leg curl, leg press, calf raises, chest press,
seated row, triceps extension, biceps curls, and modified
curl-ups. Aerobic exercise could be completed on a cycle
ergometer, treadmill, elliptical, rowing ergometer, or com-
bination. Initial exercise intensity was individualized but
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to 70-75% of VO2peak by week 6. Initial exercise dur-
ation was also individualized but generally began between
15–30 minutes/session and achieved 25–30 minutes/
session by week 4 (STAN and COMB) or 50–60 minutes/
session by week 6 (HIGH). Exercise trainers could modify
the exercise prescription or progression based on the
patient’s response to the exercise and chemotherapy
(i.e., toxicities). Unsupervised exercise was permitted but
not encouraged.
Assessment of exercise adherence
The primary outcome measure for this study was the per-
centage of supervised exercise sessions completed, defined
as the number of supervised exercise sessions attended
divided by the number of supervised exercise sessions pre-
scribed. The number of supervised exercise sessions pre-
scribed was calculated from the time of randomization
until three weeks after the final chemotherapy infusion,
and therefore could vary by the length of the chemother-
apy protocol as well as any chemotherapy delays. We did
not include unsupervised sessions in our estimate of exer-
cise adherence because, while unsupervised sessions were
permitted, they were not encouraged and only 12% of all
sessions were unsupervised [4]. Moreover, we focused on
attendance because patients achieved their prescription
goal in terms of intensity and duration, or weight, sets and
repetitions in over 90% of their supervised sessions. Exer-
cise adherence data were recorded by the exercise trainers
at every supervised session.
Assessment of predictors
Exercise predictors included standard demographic and
cancer variables, health-related fitness variables, and
patient-reported outcome variables. Demographic data
were collected by self-report and consisted of age (years),
marital status (not married versus married), education (six
categories ranging from some high school to completed
graduate school), annual family income (six categories
ranging from < $20,000 to ≥ $100,000), employment status
(not employed full-time versus employed full-time), ethni-
city (other versus white), and location/center (Ottawa ver-
sus Edmonton versus Vancouver). Cancer variables were
collected from medical records and consisted of disease
stage (I/IIa versus IIb/III based on comparing primarily
“node negative” or local disease versus primarily “node
positive” or regional disease), type of surgery (lumpectomy
versus mastectomy), and several chemotherapy variables
including taxane versus no taxane, anthracycline versus
no anthracycline, Herceptin versus no Herceptin, FEC-D
(5-fluorouracil, epirubicin, cyclophosphamide, docetaxel)
versus no FEC-D, concurrent versus sequential taxane, and
4 cycle (12 week) versus 6+ cycle (18+ week) protocols.
Other medical data consisted of self-reported comorbidities(0 versus 1+) and self-reported exercise limitations (none/
a little versus somewhat/a lot/completely). Behavioral vari-
ables were collected from self-report and consisted of
smoking behavior (nonsmoker versus smoker) and base-
line exercise behavior coded as meeting or not meeting
current aerobic or resistance exercise guidelines.
Health-related fitness assessments have been described
elsewhere [4] and consisted of variables related to peak
oxygen consumption (VO2peak), muscular strength and
endurance, body weight and height to calculate body
mass index, and dual x-ray absorptiometry for the assess-
ment of whole body fat and lean tissue. Patient-reported
outcomes have also been detailed elsewhere [4] and con-
sisted of the Medical Outcomes Survey Short Form (SF)-
36 physical component scales, physical well-being, breast
cancer symptoms, fatigue symptoms, taxane/neuropathy
symptoms, and endocrine symptoms.
Statistical analyses
Our study was originally powered for its primary purpose
of examining the effects of exercise on patient-reported
physical functioning [4]. For the present analyses, the 301
patients provided 80% power (two-tailed alpha < 0.05) to
detect a small correlation between a predictor variable
and exercise adherence of approximately r = 0.15. For
nominal variables with more than two categories, we cre-
ated a priori dichotomies based on standard groupings
where possible (e.g., married versus not married, employed
versus not employed). In the case of nominal variables
with more than two categories that could not be dichot-
omized (i.e., group assignment and location/center),
we created dummy-coded variables to allow for inclusion
in a multivariate regression analysis. All continuous vari-
ables were analyzed as such (e.g., health-related fitness
and patient-reported outcomes) although for ease of
interpretation we also present categorical variables based
on either statistically-determined tertiles or clinically
established cut-points. We initially analyzed all predictor
variables using Pearson r correlations. Variables that had
statistically significant or borderline significant (p < 0.10)
univariate associations with exercise adherence were
included in a stepwise multivariate regression analyses.
We also tested 12 interactions between the categorical
demographic/medical variables and group assignment
using analyses of variance.
Results
Participant flow through the trial has been reported else-
where [4]. Briefly, we randomized 301 of 728 (41%) eli-
gible patients between April 2008 and September 2011.
Study participants had a mean age of 50 years (SD = 9),
65% were married, 65% had completed university, 23%
were obese, 68% had stage I/IIa disease, 57% received
breast conserving surgery, 34% received FEC-D, 30%
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reported regular resistance exercise at baseline. We ob-
tained exercise adherence data on all 301 patients. The
mean length of the exercise intervention was 16.4 weeks
(SD = 3.6) resulting in an average of 49 (SD = 11) pos-
sible exercise sessions. Overall mean adherence to the
supervised exercise sessions was 73% (SD = 24%).
Predictors of adherence to supervised exercise
There were 16 significant or borderline significant univari-
ate associations between the predictors and exercise ad-
herence which are summarized in Tables 1 (demographic/
medical/behavioral), 2 (health-related fitness), and 3 (pa-
tient-reported outcomes). Variables that did not predict
adherence in univariate analyses included all demographic
factors (i.e., age, marital status, education, income, and
ethnicity); several cancer variables (i.e., type of surgery, re-
ceipt of taxanes, anthracyclines, or Herceptin); and the
patient-reported outcomes of physical functioning, fatigue,
and breast cancer symptoms.Table 1 Significant demographic, medical, and behavioral pre
Trial, 2008–2011, Canada
Variable M ± SD (%)
Group assignment
Standard aerobic (n = 96) 78% ± 24%
Combined (n = 104) 71% ± 23%
High aerobic (n = 101) 70% ± 25%
Location/Center
Ottawa (n = 84) 63% ± 27%
Edmonton (n = 117) 68% ± 23%
Vancouver (n = 100) 88% ± 13%
Baseline Aerobic Exercise
Not meeting guidelines (n = 210) 71% ± 25%
Meeting guidelines (n = 91) 78% ± 21%
Exercise limitations
Not at all/a little (n = 150) 76% ± 22%
Somewhat/a lot/completely (n = 151) 70% ± 26%
Comorbidities
0 (n = 135) 76% ± 23%
≥1 (n = 166) 70% ± 24%
Length of chemotherapy protocol
12 weeks (n = 89) 78% ± 21%
≥18 weeks (n = 212) 71% ± 25%
FEC-D3
No (n = 200) 75% ± 22%
Yes (n = 101) 68% ± 27%
Note. 1Tested the association as a continuous variable. 2Tested the association as a
cyclophosphamide, docetaxel.The 16 significant or borderline significant univariate
predictors were included in a stepwise entry regression
analysis. In the multivariate model, six predictors en-
tered the model and explained 26.4% (p < 0.001) of the
variance in exercise adherence (Table 4). The six signifi-
cant independent predictors were location/center (β =
0.41; p < 0.001), endocrine symptoms (β = 0.14; p = 0.009),
group assignment (β = −0.13; p = 0.009), exercise limita-
tions (β = −0.13; p = 0.009), length of chemotherapy proto-
col (β = −0.12; p = 0.015), and VO2peak (β = −0.12; p =
0.017). Higher exercise adherence was achieved by breast
cancer patients in Vancouver, with fewer endocrine symp-
toms, randomized to STAN, with fewer exercise limita-
tions, receiving shorter chemotherapy protocols, and with
higher VO2peak at baseline.
Interactions between predictor variables and group
assignment
Significant interactions between the predictor variables
and group assignment were identified for disease stagedictors of adherence to supervised exercise in the CARE
Correlation1 ANOVA2
r; p value F; p value
-.13; 0.025 3.1; 0.048
.42; <0.001 37.8; <0.001
.14; 0.015 5.1; 0.024
-.10; 0.098 5.8; 0.017
-.04; 0.54 4.0; 0.047
-.13; 0.031 4.7; 0.031
-.14; 0.013 6.2; 0.013
predefined categorical variable. 3FEC-D = 5-fluorouracil, epirubicin,
Table 2 Significant health-related fitness predictors of adherence to supervised exercise in the CARE Trial, 2008–2011,
Canada
Correlation1 ANOVA2
Variable M ± SD (%) r; p value F; p value
VO2peak, ml/kg/min .16; 0.006 4.3; 0.015
< 25 (n = 100) 69% ± 25%
25-30 (n = 92) 72% ± 24%
> 30 (n = 109) 78% ± 23%
Peak rating of perceived exertion (0–10) .27; <0.001 30.7; < 0.001
<10 (n = 195) 68% ± 25%
10 (n = 106) 83% ± 20%
Peak respiratory exchange ratio .31; <0.001 17.9; <0.001
≤ 1.10 (n = 123) 66% ± 26%
> 1.10 (n = 178) 78% ± 21%
Leg Strength, kg .25; <0.001 7.4; 0.001
< 70 (n = 111) 67% ± 27%
70-90 (n = 88) 74% ± 23%
> 90 (n = 102) 79% ± 20%
Body fat,% -.20; <0.001 2.8; 0.062
< 34 (n = 94) 77% ± 25%
34-42 (n = 109) 74% ± 23%
> 42 (n = 98) 68% ± 24%
Lean body mass, kg .16; <0.001 4.5; 0.012
< 37 (n = 84) 67% ± 27%
37-42 (n = 112) 72% ± 24%
> 42 (n = 105) 78% ± 21%
Note. 1Tested the association as a continuous variable. 2Tested the association as a predefined categorical variable.
Table 3 Significant patient-reported outcome predictors
of adherence to supervised exercise in the CARE Trial,
2008–2011, Canada
Correlation1 ANOVA2
Variable M ± SD (%) r; p value F; p value
Physical well-being .12; 0.036 2.5; 0.081
< 23 (n = 98) 69% ± 24%
23-25.9 (n = 93) 74% ± 25%
≥ 26 (n = 110) 76% ± 24%
Taxane/neuropathy symptoms .17; .003 3.2; 0.043
< 61 (n = 83) 68% ± 25%
61-63 (n = 102) 73% ± 24%
64 (n = 116) 77% ± 23%
Endocrine symptoms .17; 0.003 1.5; 0.21
≤ 65 (n = 104) 70% ± 24%
66-71 (n = 99) 74% ± 23%
> 71 (n = 98) 75% ± 25%
Note. 1Tested the association as a continuous variable. 2Tested the association
as a predefined categorical variable.
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interaction = 0.030). For disease stage (Figure 1), patients
with stage I/IIa disease (n = 204) adhered equally well to
all three exercise interventions whereas patients with
stage IIb/III disease (n = 96) adhered better to the STAN
intervention than the two higher dose exercise interven-
tions. For body mass index (Figure 2), healthy weight pa-
tients (n = 148) adhered equally well to all three exercise
interventions whereas overweight patients (n = 83) ad-
hered best to STAN and worst to COMB; and obeseTable 4 Significant multivariate predictors of adherence
to supervised exercise in the CARE Trial, 2008–2011,
Canada
Variable Standardized beta (β) p value
Location/Center 0.41 < 0.001
Endocrine symptoms 0.14 0.009
Group assignment −0.13 0.009
Exercise limitations −0.13 0.009
Length of chemotherapy protocol −0.12 0.015






























Figure 1 Significant interaction between disease stage and group
assignment for predicting exercise adherence. STAN = standard
aerobic exercise program; HIGH = high volume aerobic exercise
program; COMB= combined aerobic and resistance exercise program.
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HIGH.
Discussion
To our knowledge, only one other study has examined the
predictors of exercise adherence during breast cancer
chemotherapy [2]. Numerous studies have examined the
cross-sectional correlates of exercise participation in breast
cancer survivors, usually focusing on social cognitive vari-
ables and long term breast cancer survivors [13-19].
Moreover, several studies have examined the prospect-
ive correlates of exercise participation in breast can-
cer survivors [20,21] or the predictors of adherence to a
prescribed exercise program in long term breast cancer
survivors [22,23]. The determinants of exercise adherence
during breast cancer chemotherapy may be quite different






























Figure 2 Significant interaction between body mass index and
group assignment for predicting exercise adherence. STAN=
standard aerobic exercise program; HIGH = high volume aerobic exercise
program; COMB= combined aerobic and resistance exercise program.of these treatments. Moreover, none of these previous
studies have examined adherence to different types and
doses of exercise.
Overall adherence to supervised exercise in the CARE
trial was 73%. In our START trial involving breast cancer
patients receiving chemotherapy, adherence to the aerobic
exercise and resistance exercise interventions was about
70% each [2]. Adherence to the STAN intervention in the
CARE Trial, which is comparable to the aerobic exercise
intervention in the START Trial, was 78% suggesting
slightly better adherence in CARE despite the more diffi-
cult chemotherapy treatments containing taxanes. These
adherence rates are within the range reported for other
trials of exercise during cancer treatments [1]. Neverthe-
less, adherence in the CARE Trial was still not optimal
and a better understanding of the determinants of adher-
ence may inform behavior support interventions.
The strongest predictor of exercise adherence in the
CARE Trial was the location/center at which the exercise
was performed with Vancouver participants achieving
higher adherence than Edmonton or Ottawa participants.
We previously reported the same finding in our START
Trial and offered several possible explanations [2]. One
explanation was that Vancouver participants may have re-
ceived more personal attention because the fitness center
in Vancouver was only training CARE Trial participants
whereas the Edmonton fitness center was training partici-
pants from multiple trials and the Ottawa fitness center
was open to staff and patients not participating in clinical
trials. This focus on breast cancer patients in Vancouver
may have provided the women with more one-on-one at-
tention to address individual needs. Moreover, we made a
similar observation in our Alberta Physical Activity and
Breast Cancer Prevention (ALPHA) Trial where we observed
higher adherence to supervised exercise in Edmonton than
Calgary [24]. We noted that the Edmonton training facility
was exclusively for clinical trial participants whereas the
Calgary training facility was a community-based facility
open to the public [24]. Other possible explanations for
site differences include: (a) the more moderate climate in
Vancouver compared to harsher winters in Edmonton and
Ottawa, (b) possible demographic differences in each city,
(c) different referral patterns at each cancer center, and (d)
travel time and convenience of accessing each fitness cen-
ter. Future multicenter exercise trials should continue to
report on adherence differences across sites.
Our trial also demonstrated that adherence to the STAN
intervention was better than for the two higher dose exer-
cise interventions. In some ways, this finding is not sur-
prising given the many side effects of chemotherapy that
may influence the amount of exercise completed during
chemotherapy [7,8]. Nevertheless, it is unclear why doing
more exercise during an exercise session (double the dur-
ation) would have an impact on the number of exercise
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trainers instructed patients to complete only as much ex-
ercise as they were willing and able to do each session.
One possible explanation is that when breast cancer pa-
tients were making a judgment about whether to attend
their exercise session, they were factoring in the amount
of time and/or anticipated difficulty of the session. Pa-
tients experiencing some fatigue, pain, hot flashes, nausea,
or other symptoms that occurred during chemotherapy
(i.e., after our baseline assessment of symptoms) might
have felt that a 25–30 minute exercise session would be
tolerable but not a 50–60 minute aerobic or combined
exercise session. Moreover, patients with busy lives and
additional medical appointments might have felt that a
25–30 minute exercise session was more feasible than a
50–60 minute session. Based on our clinical observa-
tions, it is possible that 50–60 minutes of aerobic or
combined exercise may be close to the “maximum toler-
ated dose” of exercise for breast cancer patients receiving
current chemotherapy protocols.
Interestingly, the CARE trial showed that endocrine
symptoms (e.g., hot flashes, night sweats) at baseline were
negative predictors of exercise adherence in breast cancer
patients. To our knowledge, the CARE trial is the first to
report this association. It seems intuitive that these types
of symptoms may interfere with a patient’s ability and
willingness to engage in exercise during chemotherapy.
Nevertheless, the primary results of the CARE Trial actu-
ally showed that the higher dose exercise interventions
were superior to STAN for managing endocrine symp-
toms [4]. Consequently, strategies to help breast cancer
patients maintain exercise while experiencing such symp-
toms are needed (e.g., removing wigs, lighter clothing,
cooler environments, personal fans).
Our trial also showed that exercise adherence during
chemotherapy is predicted by the length of the chemo-
therapy protocol. Again, to our knowledge, the CARE
Trial is the first to report that the length of the chemo-
therapy protocol may influence exercise adherence. It
is well-known that the adverse effects of chemotherapy
accumulate over the course of each cycle, and these
accumulating side effects may interfere with exercise
adherence [7,8]. Nevertheless, it is also possible that
the lower adherence rate during longer chemotherapy
protocols may simply reflect the difficulty of adhering
to a longer exercise program. Unfortunately, we did
not collect data on any toxicities during chemother-
apy which might have directly informed this question.
Consequently, these data only indirectly support the idea
that chemotherapy toxicity may be the driving factor be-
hind poorer exercise adherence to longer chemotherapy
protocols. Regardless, additional support for patients
on longer and/or more toxic chemotherapy protocols
may be needed.Patients with higher aerobic fitness and fewer functional
problems also achieved better adherence. We observed
the same finding in the START Trial [2]. It is possible that
a minimum fitness level is needed to allow breast cancer
patients to tolerate and respond to exercise training dur-
ing chemotherapy. Future trials should determine if very
unfit women can benefit from exercise during chemother-
apy or whether it may be more prudent to initiate exercise
in these women after adjuvant therapies are completed. In
our paper reporting the sleep outcomes from the CARE
Trial [5], we found that only higher fit breast cancer
patients benefitted from the higher dose exercise in-
terventions. The fact that baseline aerobic fitness is a
predictor of exercise adherence is a dilemma for exer-
cise researchers. Demonstrating the benefits of an exer-
cise intervention is a precarious balance between enrolling
participants who are most likely to benefit (i.e., generally
those who are least fit) and enrolling participants who
are most likely to adhere (i.e., generally those who are
more fit).
We also identified two interesting interactions between
the predictors and group assignment suggesting that dif-
ferent exercise interventions during chemotherapy may
have different determinants of adherence. For body mass
index, healthy weight patients adhered equally well to all
three exercise interventions whereas overweight patients
adhered best to STAN and worst to COMB; and obese
patients adhered best to STAN and worst to HIGH.
These data suggest that overweight and obese patients
may struggle with higher dose exercise interventions.
Several large studies have reported that higher body
mass index is associated with lower exercise in cancer
survivors [25-27]. Given that body mass index is one of
the most consistent predictors of exercise adherence in
cancer survivors, interventions targeting obese cancer
survivors may be warranted, especially if higher dose ex-
ercise interventions are being contemplated.
For disease stage, patients with localized disease (stage
I/IIa) adhered equally well to all three exercise interven-
tions whereas patients with regional disease (stage IIb/III)
adhered better to the STAN intervention than the two
higher dose exercise interventions. In cross-sectional
studies, the role of disease stage has been mixed with
Irwin et al. [25] reporting a positive association be-
tween disease stage and exercise levels, Hong et al.
[26] reporting a small negative association, and Milne
et al. [27] reporting no association. In the START trial,
we found that patients with more advanced disease
achieved better adherence. The CARE Trial data are
consistent with the START data showing that the more
advanced stage patients had slightly better adherence to
the STAN intervention (see Figure 2) which was compar-
able to the aerobic exercise intervention in START.
However, the CARE Trial data show that these higher
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exercise interventions.
It is important to briefly note the many variables in
our study that did not predict exercise adherence either in
univariate or multivariate analyses. Variables that predicted
exercise adherence in univariate but not multivariate ana-
lyses included baseline aerobic exercise, comorbidities,
FEC-D chemotherapy, peak rating of perceived exertion,
peak respiratory exchange ratio, leg strength, lean body
mass, % body fat, physical well-being, and peripheral neur-
opathy symptoms. These variables may have relevance
for exercise adherence and should be considered in fu-
ture research. Variables that did not predict adherence,
even in univariate analyses, included all demographic fac-
tors (i.e., age, marital status, education, income, and ethni-
city); type of surgery or receipt of taxanes, anthracyclines,
or Herceptin; and the patient-reported outcomes of phys-
ical functioning, fatigue, and breast cancer symptoms.
The strengths of our study include being the first study
to prospectively examine the predictors of different types
and doses of supervised exercise in breast cancer patients
receiving chemotherapy, the assessment of many different
potential predictors, the use of an objective measure of ex-
ercise adherence, the detailed cancer data that allowed us
to examine the impact of several important chemotherapy
variables, and the large sample size that allowed us to
examine potential interactions between the predictors and
the exercise interventions. One limitation of our study is
the failure to examine predictors of long term exercise
maintenance after a structured exercise program. We have
previously reported predictors of exercise six months after
supervised exercise during chemotherapy in breast cancer
[28] and lymphoma patients [29]. In the CARE Trial, we
will have data at six months, 1 year, and 2 years to exam-
ine this issue. Another limitation is that our predictors
explained only 26% of the variance in exercise adherence,
suggesting that other important factors may affect adher-
ence. Some likely prospects include treatment toxicities and
unexpected family events that occur after randomization
which would require prospectively collecting such data.
Finally, we conducted many statistical analyses which
raises the possibility that some of the associations may be
due to chance.
In summary, we examined predictors of adherence to
three different exercise interventions in breast cancer pa-
tients receiving chemotherapy. Higher exercise adherence
was achieved by breast cancer patients in Vancouver, with
fewer endocrine symptoms, randomized to STAN, with
fewer exercise limitations, receiving shorter chemotherapy
protocols, and with higher VO2peak at baseline. Moreover,
we identified two significant interactions suggesting that
disease stage and body mass index may differentially pre-
dict adherence to the three different exercise interven-
tions. Patients who were overweight/obese or had moreadvanced disease stage adhered equally well to the stand-
ard dose aerobic exercise intervention, but struggled with
the higher dose exercise interventions. The present study
provides an empirical basis for improving exercise adher-
ence in breast cancer patients on chemotherapy, including
adherence to higher dose exercise interventions which
may provide additional benefits for symptom manage-
ment [4] and even disease-free survival [3]. Additional
research on the determinants of adherence to various ex-
ercise prescriptions during breast cancer chemotherapy
is warranted.
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